Cargando…

Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabasa, Lawrence, Kotze, Anri, Shabalala, Samukelisiwe, Kimani, Clare, Gabuza, Kwazi, Johnson, Rabia, Sangweni, Nonhlakanipho F., Maharaj, Vinesh, Muller, Christo J. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998011/
https://www.ncbi.nlm.nih.gov/pubmed/35409465
http://dx.doi.org/10.3390/ijerph19073782
_version_ 1784684840858157056
author Mabasa, Lawrence
Kotze, Anri
Shabalala, Samukelisiwe
Kimani, Clare
Gabuza, Kwazi
Johnson, Rabia
Sangweni, Nonhlakanipho F.
Maharaj, Vinesh
Muller, Christo J. F.
author_facet Mabasa, Lawrence
Kotze, Anri
Shabalala, Samukelisiwe
Kimani, Clare
Gabuza, Kwazi
Johnson, Rabia
Sangweni, Nonhlakanipho F.
Maharaj, Vinesh
Muller, Christo J. F.
author_sort Mabasa, Lawrence
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and treating the disease. The aim of the present study was to determine the therapeutic benefit of Sclerocarya birrea (Marula leaf extract, MLE) on hepatic steatosis. Obese db/db mice were randomly stratified into the obese control, metformin (MET) or MLE-treated groups. Mice were treated daily for 29 days, at which point all mice were euthanized and liver samples were collected. Hematoxylin and eosin staining was used for histological assessment of the liver sections, while qRT-PCR and Western blot were used to determine hepatic mRNA and protein expression, respectively. Thereafter, the association between methylenetetrahydrofolate reductase (Mthfr a key enzyme in one-carbon metabolism and DNA-methylation-induced regulation of gene transcription) and lipogenic genes was evaluated using Pearson’s correlation coefficient. Mice treated with MLE presented with significantly lower body and liver weights as compared with the obese control and MET-treated mice (p ≤ 0.05). Further, MLE treatment significantly inhibited hepatic steatosis as compared with the obese control and MET-treated mice (p ≤ 0.05). The reduced lipid accumulation was associated with low expression of fatty acid synthase (Cpt1; p ≤ 0.05) and an upregulation of the fatty acid oxidation gene, carnitine palmitoyltransferase (Cpt1; p ≤ 0.01), as compared with the obese control mice. Interestingly, MLE treatment improved the correlation between Mthfr and Cpt1 mRNA expression (r = 0.72, p ≤ 0.01). Taken together, the results suggest that Marula leaf extracts may inhibit hepatic steatosis by influencing the association between Mthfr and genes involved in hepatic lipid metabolism. Further studies are warranted to assess DNA methylation changes in lipid metabolism genes.
format Online
Article
Text
id pubmed-8998011
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89980112022-04-12 Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice Mabasa, Lawrence Kotze, Anri Shabalala, Samukelisiwe Kimani, Clare Gabuza, Kwazi Johnson, Rabia Sangweni, Nonhlakanipho F. Maharaj, Vinesh Muller, Christo J. F. Int J Environ Res Public Health Article Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic metabolic perturbations ranging from simple steatosis to steatohepatitis, cirrhosis and hepatocellular carcinoma. Currently, lifestyle modifications to reduce weight gain are considered the most effective means of preventing and treating the disease. The aim of the present study was to determine the therapeutic benefit of Sclerocarya birrea (Marula leaf extract, MLE) on hepatic steatosis. Obese db/db mice were randomly stratified into the obese control, metformin (MET) or MLE-treated groups. Mice were treated daily for 29 days, at which point all mice were euthanized and liver samples were collected. Hematoxylin and eosin staining was used for histological assessment of the liver sections, while qRT-PCR and Western blot were used to determine hepatic mRNA and protein expression, respectively. Thereafter, the association between methylenetetrahydrofolate reductase (Mthfr a key enzyme in one-carbon metabolism and DNA-methylation-induced regulation of gene transcription) and lipogenic genes was evaluated using Pearson’s correlation coefficient. Mice treated with MLE presented with significantly lower body and liver weights as compared with the obese control and MET-treated mice (p ≤ 0.05). Further, MLE treatment significantly inhibited hepatic steatosis as compared with the obese control and MET-treated mice (p ≤ 0.05). The reduced lipid accumulation was associated with low expression of fatty acid synthase (Cpt1; p ≤ 0.05) and an upregulation of the fatty acid oxidation gene, carnitine palmitoyltransferase (Cpt1; p ≤ 0.01), as compared with the obese control mice. Interestingly, MLE treatment improved the correlation between Mthfr and Cpt1 mRNA expression (r = 0.72, p ≤ 0.01). Taken together, the results suggest that Marula leaf extracts may inhibit hepatic steatosis by influencing the association between Mthfr and genes involved in hepatic lipid metabolism. Further studies are warranted to assess DNA methylation changes in lipid metabolism genes. MDPI 2022-03-22 /pmc/articles/PMC8998011/ /pubmed/35409465 http://dx.doi.org/10.3390/ijerph19073782 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mabasa, Lawrence
Kotze, Anri
Shabalala, Samukelisiwe
Kimani, Clare
Gabuza, Kwazi
Johnson, Rabia
Sangweni, Nonhlakanipho F.
Maharaj, Vinesh
Muller, Christo J. F.
Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title_full Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title_fullStr Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title_full_unstemmed Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title_short Sclerocarya birrea (Marula) Extract Inhibits Hepatic Steatosis in db/db Mice
title_sort sclerocarya birrea (marula) extract inhibits hepatic steatosis in db/db mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998011/
https://www.ncbi.nlm.nih.gov/pubmed/35409465
http://dx.doi.org/10.3390/ijerph19073782
work_keys_str_mv AT mabasalawrence sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT kotzeanri sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT shabalalasamukelisiwe sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT kimaniclare sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT gabuzakwazi sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT johnsonrabia sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT sangweninonhlakaniphof sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT maharajvinesh sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice
AT mullerchristojf sclerocaryabirreamarulaextractinhibitshepaticsteatosisindbdbmice